MeSH term
Frequency | Condition_Probility | Acute Disease | 2 | 0.0 |
Adult | 30 | 0.0 |
Comparative Study | 21 | 0.0 |
Humans | 82 | 0.0 |
Animals | 18 | 0.0 |
Aged | 29 | 0.0 |
Aged, 80 and over | 11 | 0.0 |
Arylsulfotransferase/genetics | 4 | 80.0 |
Case-Control Studies | 13 | 0.0 |
Female | 32 | 0.0 |
*Genetic Predisposition to Disease | 4 | 0.0 |
Genotype | 23 | 0.0 |
Glutathione Transferase/genetics | 3 | 1.0 |
Middle Aged | 32 | 0.0 |
*Polymorphism, Genetic | 13 | 0.0 |
Research Support, Non-U.S. Gov't | 52 | 0.0 |
Risk Factors | 14 | 0.0 |
Amines/*pharmacokinetics | 2 | 50.0 |
Arylamine N-Acetyltransferase/genetics/metabolism | 2 | 13.0 |
*Arylsulfotransferase | 34 | 91.0 |
Biotransformation | 7 | 1.0 |
Gene Expression Regulation, Bacterial | 2 | 3.0 |
Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Immunoblotting | 4 | 0.0 |
Isoenzymes/genetics/metabolism | 2 | 1.0 |
Mutagenicity Tests | 3 | 1.0 |
Sulfotransferases/genetics/*metabolism | 4 | 50.0 |
Enzyme Inhibitors/*pharmacology | 4 | 0.0 |
In Vitro | 7 | 0.0 |
Kinetics | 17 | 0.0 |
Liver/*enzymology | 6 | 1.0 |
Male | 28 | 0.0 |
Nitrophenols/metabolism | 3 | 13.0 |
Phosphoadenosine Phosphosulfate/metabolism | 3 | 50.0 |
Quercetin/*pharmacology | 3 | 12.0 |
Sulfotransferases/*antagonists & inhibitors/metabolism | 4 | 80.0 |
Cytosol/metabolism | 4 | 0.0 |
Glucuronosyltransferase/*metabolism | 2 | 3.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Sulfotransferases/*metabolism | 8 | 30.0 |
Regression Analysis | 2 | 0.0 |
Carcinogens/*metabolism | 2 | 2.0 |
Dose-Response Relationship, Drug | 8 | 0.0 |
Isoenzymes/metabolism | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 8 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 19 | 0.0 |
Sulfates/metabolism | 5 | 9.0 |
Arylsulfotransferase/*genetics | 3 | 42.0 |
Isoenzymes/antagonists & inhibitors/metabolism | 2 | 2.0 |
Substrate Specificity | 12 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Pregnancy | 2 | 0.0 |
Thyroid Hormones/*metabolism | 2 | 6.0 |
Alleles | 9 | 0.0 |
Amino Acid Sequence | 4 | 0.0 |
Enzyme Inhibitors/pharmacology | 5 | 0.0 |
Molecular Sequence Data | 10 | 0.0 |
Temperature | 2 | 0.0 |
Blotting, Western | 2 | 0.0 |
Liver/enzymology/*metabolism | 2 | 5.0 |
Naphthols/chemistry | 2 | 100.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Rats | 10 | 0.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
Adolescent | 6 | 0.0 |
*Alleles | 4 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Sex Factors | 3 | 0.0 |
Sulfotransferases/*genetics | 17 | 47.0 |
Age Factors | 4 | 0.0 |
Cytosol/enzymology | 4 | 2.0 |
Dopamine/metabolism | 3 | 2.0 |
Inhibitory Concentration 50 | 4 | 1.0 |
Protein Binding | 4 | 0.0 |
Base Sequence | 9 | 0.0 |
Cells, Cultured | 5 | 0.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
DNA Primers | 5 | 0.0 |
Enzyme Stability | 2 | 1.0 |
Sulfotransferases/antagonists & inhibitors/*metabolism | 2 | 66.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Arylsulfotransferase/metabolism | 2 | 40.0 |
Child, Preschool | 2 | 0.0 |
Infant | 2 | 0.0 |
Sulfotransferases/metabolism | 2 | 14.0 |
Polymorphism, Genetic | 8 | 0.0 |
Exons | 3 | 0.0 |
Japan | 2 | 0.0 |
Dehydroepiandrosterone/metabolism | 2 | 11.0 |
*Diet | 2 | 0.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Asian Continental Ancestry Group/*genetics | 3 | 0.0 |
European Continental Ancestry Group/*genetics | 3 | 0.0 |
Isoenzymes/genetics | 4 | 1.0 |
Linkage Disequilibrium | 2 | 0.0 |
Blood Platelets/*enzymology | 3 | 4.0 |
Cytosol/*enzymology | 2 | 3.0 |
Phenotype | 9 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
Histidine/chemistry | 2 | 4.0 |
Polymerase Chain Reaction | 9 | 0.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Xenobiotics/*pharmacokinetics | 2 | 12.0 |
Binding Sites/genetics | 3 | 0.0 |
Enzyme Activation/genetics | 2 | 2.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Models, Molecular | 3 | 0.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Phosphoadenosine Phosphosulfate/chemistry | 2 | 100.0 |
Substrate Specificity/genetics | 2 | 4.0 |
Catalysis | 2 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Isoenzymes/biosynthesis/genetics/metabolism | 2 | 7.0 |
Acetylation | 2 | 0.0 |
Mice | 2 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Gene Frequency | 9 | 0.0 |
Isoenzymes/*genetics | 2 | 0.0 |
Diet | 3 | 0.0 |
Drug Interactions | 2 | 0.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
*Pharmacogenetics | 2 | 4.0 |
Binding Sites | 3 | 0.0 |
Child | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/genetics | 2 | 8.0 |
Time Factors | 3 | 0.0 |
English Abstract | 2 | 0.0 |
Arylamine N-Acetyltransferase/genetics | 2 | 3.0 |
Genetic Predisposition to Disease | 5 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Odds Ratio | 3 | 0.0 |
Smoking/adverse effects | 4 | 1.0 |
Apomorphine/*metabolism | 2 | 100.0 |
Arylsulfotransferase/antagonists & inhibitors/*metabolism | 2 | 50.0 |
Dopamine Agonists/*metabolism | 2 | 66.0 |
Sulfotransferases/*genetics/metabolism | 3 | 30.0 |
Arylamine N-Acetyltransferase/*genetics | 2 | 0.0 |
Logistic Models | 2 | 0.0 |
Colorectal Neoplasms/*genetics | 3 | 1.0 |
*Smoking | 2 | 2.0 |
Polymorphism, Genetic/*genetics | 4 | 0.0 |
Sulfotransferases/*biosynthesis/genetics | 3 | 60.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Models, Chemical | 2 | 0.0 |
Mutation | 2 | 0.0 |
Sulfotransferases/*chemistry | 2 | 66.0 |
DNA Adducts | 2 | 2.0 |
Crystallography, X-Ray | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
